• 1
    Martini N,Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am. 1987; 67: 10371048.
  • 2
    Rosell R,Gomez-Codina J,Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994; 330: 153158.
  • 3
    Nagai K,Tsuchiya R,Mori T, et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg. 2003; 125: 254260.
  • 4
    De Marinis F,Gebbia V,De Petris L. Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer. Ann Oncol. 2005; 16( suppl 4): iv116iv122.
  • 5
    Vansteenkiste JF,De Leyn PR,Deneffe G.J, et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Ann Thorac Surg. 1997; 63: 14411450.
  • 6
    Suzuki K,Nagai K,Yoshida J,Nishimura M,Takahashi K,Nishiwaki Y. The prognosis of surgically resected N2 non-small cell lung cancer: the importance of clinical N status. J Thorac Cardiovasc Surg. 1999; 118: 145153.
  • 7
    Fukuse T,Hirata T,Naiki H,Hitomi S,Wada H. Prognostic significance of proliferative activity in pN2 non-small-cell lung carcinomas and their mediastinal lymph node metastases. Ann Surg. 2000; 232: 112118.
  • 8
    Singhal S,Vachani A,Antin-Ozerkis D,Kaiser L,Albedla SM. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res. 2005; 11: 39743986.
  • 9
    Hartwell LH,Kastan MB. Cell cycle control and cancer. Science. 1994; 266: 18211828.
  • 10
    Yokota J,Kohno T. Molecular footprints of human lung cancer progression. Cancer Sci. 2004; 95: 197204.
  • 11
    Zhu CQ,Shih W,Ling CH,Tsao MS. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol. 2006; 59: 790800.
  • 12
    Martin B,Paesmans M,Mascaux C, et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer. 2004; 91: 20182025.
  • 13
    Shiba M,Kohno H,Kakizawa K, et al. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected non-small cell lung carcinoma. Cancer. 2000; 89: 14571465.
  • 14
    Tomita M,Matsuzaki Y,Edagawa M,Shimizu T,Hara M,Onitsuka T. Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer. Eur J Surg Oncol. 2003; 29: 654657.
  • 15
    Berghmans T,Mascaux C,Martin B,Ninane V,Sculier J-P. Prognostic role of p53 in stage III non-small cell lung cancer. Anticancer Res. 2005; 25: 23852390.
  • 16
    Tomita M,Matsuzaki Y,Shimizu T,Hara M,Ayabe T,Onitsuka T. Vascular endothelial growth factor expression in pN2 non-small cell lung cancer: lack of prognostic value. Respirology. 2005; 10: 3135.
  • 17
    Travis WD,Brambilla E,Muller-Hermelink HK,Harris CC. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
  • 18
    The Japan Lung Cancer Society. Classification of Lung Cancer, 1st English ed. Tokyo: Kanehara & Company, Ltd.; 2000.
  • 19
    Geradts J,Fong KM,Zimmerman PV,Maynard R,Minna JD. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res. 1999; 5: 791800.
  • 20
    Burke L,Flieder DB,Guinee DG, et al. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res. 2005; 11: 232241.
  • 21
    Betticher DC,Highway J,Hasleton PS, et al. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer. 1996; 73: 294300.
  • 22
    Kaplan EL,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 23
    Peto R,Pike MC,Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples Br J Cancer. 1977; 35: 139.
  • 24
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972; 34: 187220.
  • 25
    Mehdi SA,Etzell JE,Newman NB,Weidner N,Kohman LJ,Graziano SL. Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancer. Lung Cancer. 1998; 20: 99108.
  • 26
    Yano T,Fukuyama Y,Yokoyama H, et al. Long-term survivors with pN2 non-small cell lung cancer after a complete resection with a systematic mediastinal node dissection. Eur J Cardiothorac Surg. 1998; 14: 152155.
  • 27
    Komiya T,Hosono Y,Hirashima T, et al. p21 Expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res. 1997; 3: 18311835.
  • 28
    Esposito V,Baldi A,Tonini G, et al. Analysis of cell cycle regulator proteins in non-small cell lung cancer. J Clin Pathol. 2004; 57: 5863.
  • 29
    Parry D,Mahony D,Wills K,Lees E. Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibition. Mol Cell Biol. 1999; 19: 17751783.
  • 30
    Mitra J,Dai CY,Somasundaram K, et al. Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16 (INK4a). Mol Cell Biol. 1999; 19: 39163928.
  • 31
    Yasufuku K,Chiyo M,Koh E, et al. Endobronchial ultrasound guided transbronchial needle aspiration for staging of lung cancer. Lung Cancer. 2005; 50: 347354.